TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7932943

Group type: EXPERIMENTAL
Intervention: Five‐Step Approach strategy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: non‐awareness strategy
Number of subjects: 64

Group type: COMPARATOR
Intervention: awareness strategy
Number of subjects: 64

Group type: COMPARATOR
Intervention: control condition
Number of subjects: 64
Study: 3212423

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 17187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17187

Group type: EXPERIMENTAL
Intervention: Streptokinase and aspirin
Number of subjects: 17187
Study: 30496300

Group type: EXPERIMENTAL
Intervention: Connectedness to Nature Index for Parents of Preschool Children (CNI-PPC)
Number of subjects: 299
Study: 28062552

Group type: EXPERIMENTAL
Intervention: Double-dose IIV4 (0.5 mL, 15 µg per strain)
Number of subjects: 2424
Study: 26582386

Group type: EXPERIMENTAL
Intervention: Mother-Generated Index (MGI)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Comparison instruments (EQ-5D-3 L; Edinburgh Postnatal Depression Scale; Satisfaction With Life Scale; State Trait Anxiety Inventory)
Number of subjects: 678
Study: 23325124

Group type: EXPERIMENTAL
Intervention: TTM-based intervention programme (educational materials and phone counselling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TTM-based intervention programme
Number of subjects: 0
Study: 21255503

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 16301
Study: 18308010

Group type: EXPERIMENTAL
Intervention: LRPT 150 mg/day
Number of subjects: 444

Group type: COMPARATOR
Intervention: ERN 1 g
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: ERN 1 g coadministered with LRPT 18.75, 37.5, 75, or 150 mg
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: LRPT plus ERN
Number of subjects: 444
Study: 17101299

Group type: EXPERIMENTAL
Intervention: Endoscopic gastric analysis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional gastric analysis
Number of subjects: 12
Study: 15677415

Group type: EXPERIMENTAL
Intervention: Receipt of a signal of trust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trustworthy behavior (sharing a greater proportion of monetary gains)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random monetary transfer
Number of subjects: 0
Study: 11691520

Group type: EXPERIMENTAL
Intervention: ACE inhibitors or angiotensin receptor antagonists
Number of subjects: 369

Group type: COMPARATOR
Intervention: No ACE inhibitors or angiotensin receptor antagonists
Number of subjects: 369
Study: 9145959

Group type: EXPERIMENTAL
Intervention: Glycolic acid peels (20-70%) and cream containing 10% glycolic acid and 2% hydroquinone (Neostrata AHA Age Spot and Skin Lightening Gel)
Number of subjects: 10
Study: 7910999

Group type: EXPERIMENTAL
Intervention: Flaxseed oil-containing diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1.62 g EPA and 1.08 g DHA daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Western diet)
Number of subjects: 30
Study: 2906018

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 20
Study: 30545242

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 192

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 192
Study: 29037645

Group type: EXPERIMENTAL
Intervention: Postural insoles
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo insoles (Control)
Number of subjects: 24
Study: 26299899

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy and nanocrystalline silver dressings
Number of subjects: 17

Group type: COMPARATOR
Intervention: Negative pressure wound therapy (NPWT) alone
Number of subjects: 17
Study: 23728612

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (25 mg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 21417561

Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 60 min supervised aerobic dance and strength training at least twice per week for a minimum of 12 weeks.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (CG) - No specific intervention mentioned.
Number of subjects: 105
Study: 19139427

Group type: EXPERIMENTAL
Intervention: tremelimumab 10 mg/kg once every month
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: tremelimumab 15 mg/kg every 3 months
Number of subjects: 28
Study: 17198089

Group type: EXPERIMENTAL
Intervention: Chemoradioimmunotherapy with low-dose Interferon-alpha injection before therapy (arm A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (arm B)
Number of subjects: 44
Study: 15490187

Group type: EXPERIMENTAL
Intervention: FF-CATS
Number of subjects: 40

Group type: COMPARATOR
Intervention: FACT charts
Number of subjects: 40
Study: 12140732

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil, 8-16 mg
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5000
Study: 10025070

Group type: EXPERIMENTAL
Intervention: DFT+ energies
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 2 x DFT+
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Maximum energy (34 J)
Number of subjects: 83
Study: 8050380

Group type: EXPERIMENTAL
Intervention: Clomipramine 75 mg tablet (increased to 150 mg if necessary) for 8 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo tablet for 8 weeks
Number of subjects: 181
Study: 3291940

Group type: EXPERIMENTAL
Intervention: Adrenaline 1.0%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dipivalyl epinephrine (Propine) 0.1%
Number of subjects: 0
Study: 30310037

Group type: EXPERIMENTAL
Intervention: Virtual Bronchoscopic Navigation (VBN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation (EMN)
Number of subjects: 0
Study: 28295312

Group type: EXPERIMENTAL
Intervention: ADHD group (treated with stimulant medication)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: ADHD group with Consistent or Inconsistent medication pattern
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: ADHD group with Consistent pattern
Number of subjects: 579
Study: 26394813

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm sealing (EVAS) with the Nellix device
Number of subjects: 25
Study: 22540523

Group type: EXPERIMENTAL
Intervention: Nutritional education program based on the BASNEF educational model
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study: 21180681

Group type: EXPERIMENTAL
Intervention: Provisional abutment (PA)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Definitive abutment (DA)
Number of subjects: 25
Study: 18788966

Group type: EXPERIMENTAL
Intervention: Legacy intervention (three home visits to construct a personal Legacy, usually a scrapbook with photographs or audiotaped stories)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Legacy intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Supportive telephone calls (control group)
Number of subjects: 42
Study: 17272946

Group type: EXPERIMENTAL
Intervention: School-based program of eating disorder prevention (75 participants)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (64 participants)
Number of subjects: 139
Study: 12811711

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine (2.5-10.0 mg)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718

Group type: COMPARATOR
Intervention: Haloperidol (7.5 mg)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Lorazepam (2.0 mg)
Number of subjects: 718
Study: 11010930

Group type: EXPERIMENTAL
Intervention: Laurate (10 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palmitate (10 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stearate (10 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oleate (10 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elaidate (10 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linoleate (10 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linolenate (10 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methyl-labeled fatty acids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboxyl-labeled fatty acids
Number of subjects: 0
Study: 8772622

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg b.i.d.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metoprolol CR 100 mg once daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 34
Study: 1292771

Group type: EXPERIMENTAL
Intervention: MRI and MR cholangiography (MRC) using hepatobiliary contrast media (Mn‐DPDP, Gd‐BOPTA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ultrasound, CT, and invasive techniques (ERCP)
Number of subjects: 65
Study: 6721260

Group type: EXPERIMENTAL
Intervention: Dialysed alum adsorbed extract of grass pollens
Number of subjects: 58

Group type: COMPARATOR
Intervention: Allpyral (undialysed pyridine extracted alum precipitated extract of grass pollens)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 58
Study: 30262574

Group type: EXPERIMENTAL
Intervention: Subcutaneous tinzaparin 100 IU·kg‐1 once a day for 12 weeks
Number of subjects: 549

Group type: COMPARATOR
Intervention: Control group (no treatment in addition to standard of care)
Number of subjects: 549
Study: 24453078

Group type: EXPERIMENTAL
Intervention: Ofatumumab (100 mg, 300 mg, or 700 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 22417028

Group type: EXPERIMENTAL
Intervention: Perioperative beta-blockade
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: Perioperative beta-blockers
Number of subjects: 8351

Group type: COMPARATOR
Intervention: No perioperative beta-blockers (Control)
Number of subjects: 8351
Study: 20431994

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning procedure pairing alcohol-related cues with negative stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evaluative conditioning procedure pairing alcohol-related cues with neutral stimuli
Number of subjects: 0
Study: 18560788

Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) 2 x 15 g/day for 2 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistant Starch with Wheat Bran (RS+WB) 2 x 15 g RS + 2 x 6 g WB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15834291

Group type: EXPERIMENTAL
Intervention: Lacidipine (calcium antagonist)
Number of subjects: 2259

Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 2259

Group type: EXPERIMENTAL
Intervention: Cross-sectional quality control
Number of subjects: 2259

Group type: EXPERIMENTAL
Intervention: Longitudinal quality control
Number of subjects: 2259
Study: 12804926

Group type: EXPERIMENTAL
Intervention: High dose AR‐H040922 (13.3 microg/kg/min)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Low dose AR‐H040922 (6.7 microg/kg/min)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: AR‐H040922 (both doses)
Number of subjects: 82
Study: 10821460

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin replacement therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subcutaneous immunoglobulin replacement therapy
Number of subjects: 40
Study: 8899085

Group type: EXPERIMENTAL
Intervention: 8 mg loperamide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 12 mg loperamide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood sugar measurement
Number of subjects: 16
Study: 1739446

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6861809

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin retard
Number of subjects: 0
Study: 30111222

Group type: EXPERIMENTAL
Intervention: Mobile application assistance (AED-Quebec)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Verbal assistance
Number of subjects: 52

Group type: COMPARATOR
Intervention: No assistance
Number of subjects: 52
Study: 30377212

Group type: EXPERIMENTAL
Intervention: Physical activity programme supported by behavioural change techniques (8 visits of supervised activity sessions and 12 telephone support calls over 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 26930534

Group type: EXPERIMENTAL
Intervention: Lifestyle Balance treatment intervention (n = 60)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care control (n = 62)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 25108493

Group type: EXPERIMENTAL
Intervention: Coronary anatomy assessment via blinded film review
Number of subjects: 1787

Group type: EXPERIMENTAL
Intervention: Revascularization strategy assessment via blinded film review
Number of subjects: 1787

Group type: COMPARATOR
Intervention: SYNTAX score comparison across revascularization strategies
Number of subjects: 1787
Study: 22955097

Group type: EXPERIMENTAL
Intervention: Twenty‐ to 30‐minute brief intervention (education and motivational interview)
Number of subjects: 104
Study: 20676609

Group type: EXPERIMENTAL
Intervention: Cereboost™ (100 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cereboost™ (200 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cereboost™ (400 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cereboost™ (100 mg, 200 mg, 400 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 17430413

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 19
Study: 16317275

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy (3DCRT)
Number of subjects: 10
Study: 12206264

Group type: EXPERIMENTAL
Intervention: Radiofrequency tissue ablation (2,800 J per treatment session under local anesthesia)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Radiofrequency tissue ablation
Number of subjects: 20
Study: 10986574

Group type: EXPERIMENTAL
Intervention: Support group (patients and their partners, n = 16)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (patients only, n = 13)
Number of subjects: 29
Study: 8615349

Group type: EXPERIMENTAL
Intervention: High-intensity strength training (2 days/week, 5 different exercises)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 39
Study: 1447035

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy (5‐FU/FAM) alone, radiation therapy alone, or chemotherapy+radiation therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy and radiation therapy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (radiation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No radiation
Number of subjects: 120
Study: 3905064

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 768

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 768
Study: 31537107

Group type: EXPERIMENTAL
Intervention: Ubrogepant (100 mg, 2 x 50 mg tablets)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Ubrogepant
Number of subjects: 518
Study: 29895072

Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Metal Stent (FC-SEMS)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Partially Covered Self-Expandable Metal Stent (PC-SEMS)
Number of subjects: 98
Study: 26311660

Group type: EXPERIMENTAL
Intervention: Staggered meal (86g beans consumed 15min before the rest of the meal)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control meal (86g beans consumed with the rest of the meal)
Number of subjects: 28
Study: 25514077

Group type: EXPERIMENTAL
Intervention: Atomized buccal midazolam (0.3 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atomized intranasal midazolam (0.3 mg/kg)
Number of subjects: 25
Study: 22776782

Group type: EXPERIMENTAL
Intervention: Extended Hemodialysis (eHD)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional Hemodialysis (cHD)
Number of subjects: 8
Study: 19857542

Group type: EXPERIMENTAL
Intervention: Funciona™ (antioxidant functional food beverage)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 400
Study: 17608947

Group type: EXPERIMENTAL
Intervention: Colonic stenting as bridge to elective surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Emergency surgery (current standard treatment)
Number of subjects: 120
Study: 16258576

Group type: EXPERIMENTAL
Intervention: Strong Parents-Strong Children programme (6-week behavioural intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wait-list control design)
Number of subjects: 0
Study: 12435257

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 4052

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 4052
Study: 10202575

Group type: EXPERIMENTAL
Intervention: CCK-4 bolus injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipatory anxiety scan
Number of subjects: 0
Study: 7847642

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole (450 mg/m2 body surface area intravenously daily for 5 days and then weekly for 48 weeks, plus levamisole 50 mg orally three times/d for 3 days, repeated every 2 weeks for 1 year)
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Levamisole alone (50 mg orally three times/d for 3 days, repeated every 2 weeks for 1 year)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 929
Study: 2335063

Group type: EXPERIMENTAL
Intervention: Nutrition education program (learning by teaching)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (non-equivalent)
Number of subjects: 8
Study: 31081404

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC, 50 mg)
Number of subjects: 160
Study: 28904053

Group type: EXPERIMENTAL
Intervention: 40 mg olmesartan + 12.5 mg hydrochlorothiazide (OH)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: 80 mg telmisartan + 5 mg amlodipine (TA)
Number of subjects: 481
Study: 25907406

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I), 5 sessions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 23
Study: 22618564

Group type: EXPERIMENTAL
Intervention: Carpal tunnel release with nerve conduction studies (n = 45)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Carpal tunnel release without nerve conduction studies (n = 48)
Number of subjects: 93
Study: 21311416

Group type: COMPARATOR
Intervention: Isoflavones 60 mg + Lactobacillus sporogenes + calcium and vitamin D3 (E)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Magnolia bark extract + Isoflavones + Lactobacillus sporogenes + calcium and vitamin D3 (ES)
Number of subjects: 634

Group type: COMPARATOR
Intervention: Both E and ES
Number of subjects: 634

Group type: COMPARATOR
Intervention: E
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: ES
Number of subjects: 634
Study: 19289934

Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trial (RCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 16954712

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.25%
Number of subjects: 40
Study: 15577584

Group type: EXPERIMENTAL
Intervention: 1110 MBq (30 mCi) 131I dose
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 3700 MBq (100 mCi) 131I dose
Number of subjects: 155
Study: 11912569

Group type: EXPERIMENTAL
Intervention: Bupropion, Sertraline, Venlafaxine (doses: bupropion 450 mg/day, sertraline 200 mg/day, venlafaxine 375 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Continuation phase (not specified which antidepressant continued)
Number of subjects: 64
Study: 9396908

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 69

Group type: COMPARATOR
Intervention: No epidural anesthesia
Number of subjects: 69
Study: 8164529

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy exertion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate amounts of exercise
Number of subjects: 0
Study: 3073870

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg/day prednisolone for 3 weeks, then 0.3 mg/kg for a fourth week + 5 MU/m2 i.m. interferon for 12 weeks (5 days daily then three times a week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo + 5 MU/m2 i.m. interferon for 12 weeks (5 days daily then three times a week)
Number of subjects: 20
Study: 30045336

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 80
Study: 26804973

Group type: EXPERIMENTAL
Intervention: Standardized differential explanations of voice-hearing
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Reported behavioral intentions
Number of subjects: 1004
Study: 25697549

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Lactobacillus fermentum CECT5716 (experimental group, EG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control formula without Lactobacillus fermentum CECT5716 (control group, CG)
Number of subjects: 0
Study: 23588255

Group type: EXPERIMENTAL
Intervention: NSAID (Ibumetin NYCOMED GmbH Plant Oranienburg Germany (600 mg) × 3/day/1 week)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20004356

Group type: EXPERIMENTAL
Intervention: Intravenous alpha-lipoic acid (ALA), administered daily for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo, administered daily for 3 weeks
Number of subjects: 30
Study: 19057167

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0